Glioblastoma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - VBL Therapeutics, Diffusion Pharma, Bayer, AstraZeneca, DNAtrix, Chimerix, Karyopharm Therapeutics, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeut

DelveInsight's "Glioblastoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glioblastoma Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Glioblastoma market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Glioblastoma: An Overview
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed.

GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative.

Glioblastoma Market Key Facts
As per National Cancer Institute, 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in death.
According to the study by Waschke et al., (2018), approximately 7,000 new cases of malignant brain tumors arise annually in Germany with glioblastoma being the most common malignant brain tumor.
As per DelveInsight, the total diagnosed incident population of GBM in the 7 major markets was 29,400+ in 2020.
The total diagnosed incident cases of GBM patients were maximum in males as compared to females in the 7 MM during the study period of 2019-2032.
In the case of GBM patients in the United States, the diagnosed incident cases were 15,400+ in 2020.
In the EU5 countries, the diagnosed incident population of GBM was found to be maximum in Germany followed by France in 2020. While Spain accounted for the lowest diagnosed incident population in 2020.
Japan accounted for 1,950+ diagnosed incident cases of GBM in 2020.
According to DelveInsight's analysis, GBM is more prevalent among males than females

Find a sample copy of the Glioblastoma Market report at:
https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Market
As per DelveInsight, the Glioblastoma market size in the seven major markets was USD 1,022.1 Million in 2020, which is expected to increase during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Glioblastoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Glioblastoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request a sample and discover more about the report offerings:
https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Epidemiology
The epidemiology section covers detailed insights into the historical and current Glioblastoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Explore more about the Glioblastoma Epidemiology:
https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Epidemiology Segmentation
Total Diagnosed Incident Population of Glioblastoma Multiforme
Gender-specific Diagnosed Incidence of Glioblastoma Multiforme
Diagnosed Incident Population-based on Primary Site Of Glioblastoma Multiforme
Age-specific Diagnosed Incidence of Glioblastoma Multiforme
Type-specific Diagnosed Incidence of Glioblastoma Multiforme
Diagnosed Incident Population-based on HistologicClassification of Glioblastoma Multiforme

Glioblastoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma market or expected to get launched in the market during the study period. The analysis covers Glioblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Glioblastoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for a sample report to understand more about the Glioblastoma pipeline development activities:
https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Therapeutics Assessment
Glioblastoma Therapies covered in the report include:
Ofranergene obadenovec
Trans Sodium Crocetinate
Regorafenib
Durvalumab
DNX-2401
ONC201
Selinexor (KPT-330)
Paxalisib (GDC-0084)
AV-GBM-1
MDNA55
VAL-083
And many more

Some of the key companies in the Glioblastoma Market include:
VBL Therapeutics
Diffusion Pharmaceuticals
Bayer
AstraZeneca
DNAtrix
Chimerix
Karyopharm Therapeutics
Kazia Therapeutics
Aivita Biomedical
Medicenna Therapeutics
Kintara Therapeutics
Ana many others

Learn more about the emerging therapies & key companies in the Glioblastoma Therapeutics Market:
https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glioblastoma Competitive Intelligence Analysis
4. Glioblastoma Market Overview at a Glance
5. Glioblastoma Disease Background and Overview
6. Glioblastoma Patient Journey
7. Glioblastoma Epidemiology and Patient Population
8. Glioblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Glioblastoma Unmet Needs
10. Key Endpoints of Glioblastoma Treatment
11. Glioblastoma Marketed Products
12. Glioblastoma Emerging Therapies
13. Glioblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Glioblastoma Market Outlook (7 major markets)
16. Glioblastoma Access and Reimbursement Overview
17. KOL Views on the Glioblastoma Market.
18. Glioblastoma Market Drivers
19. Glioblastoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Glioblastoma Market report here:
https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.